甲状腺癌液体活检相关标志物临床应用专家共识OA

In recent years,liquid biopsy has demonstrated broad clinical application prospects in cancer diagnosis and treatment owing to its advantages of minimal invasiveness and good repeatability.However,its clinical application in early diagnosis,prognostic evaluation,treatment selection,and efficacy monitoring of thyroid cancer still lacks a unified expert consensus.To address this issue,the Thyroid Cancer Biomarkers Collaborative Group of Tumor Marker Committee of China Anti-Cancer Association,combined with the Thyroid Disease Professional Committee of the Chinese Research Hospital Association,assembled a consensus expert group organizing 32 experts from 24 tertiary grade-A hospitals nationwide in the fields of thyroid surgery,medical oncology,laboratory medicine,and evidence-based medicine.A systematic search was conducted on the data in PubMed,Embase,and the Cochrane Library(from inception to February 2025),and 90 studies related to liquid biopsy in thyroid cancer were finally included.Based on GRADE quality grading,a 4-level system for rating the certainty of a body of evidence(high/moderate/low/very low),combined with expert clinical experience,the expert group formulated recommendations through 2 rounds of modified Delphi questionnaires(consensus defined as≥75％agreement among experts)and thereby developed the Expert Consensus on Clinical Application of Liquid Biopsy-related Biomarkers in Thyroid Cancer.Focusing on the clinical scenarios of diagnosis,prognostic evaluation,treatment selection,and efficacy monitoring of liquid biopsy in papillary,follicular,medullary,and anaplastic thyroid cancer,this consensus established 10 recommendations covering each pathological subtype and overall non-recommended scenarios,including 7 strong recommendations and 3 weak recommendations.This consensus provides supplementary decision-making references for clinicians when conventional diagnostic methods remain uncertain,and encourages liquid biopsy-related testing within the framework of clinical research,so as to promote the standardized application of liquid biopsy techniques in the diagnosis and treatment of thyroid cancer.